Why some dialysis patients don't respond to anemia medicine
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at why some people on dialysis don't respond well to anemia medicines (called ESAs). It aims to help doctors understand and better treat anemia in dialysis patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have kidney failure and are on hemodialysis (a machine that cleans your blood).
- You have been on hemodialysis for at least 3 months.
- You are currently taking medicine for anemia (like erythropoietin or similar).
- You are expected to stay on dialysis during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
This trial tests whether a medicine called spironolactone can help children on hemodialysis who still have anemia despite usual treatment. It aims to see if this drug improves red blood cell production better than standard care alone.
This study looks at blood markers related to iron and other body processes (like minerals, liver function, and inflammation) in people receiving hemodialysis. The results may help doctors better understand what affects health in dialysis patients.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This study tests whether a medication called erythropoietin (a hormone that helps your body make red blood cells) can improve hemoglobin levels in people on dialysis. It also looks at whether metabolic syndrome (a group of conditions like high blood pressure and high blood sugar) makes the medicine less effective.
This trial tests whether adding romiplostim (a medication that helps increase blood cells) to standard ESA therapy can improve anemia in people on dialysis who have not responded well to ESAs alone.
Hear when a new Hemodialysis Complication trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.